AMGN Amgen Inc.

Price (delayed)

$223.39

Market cap

$130.84B

P/E Ratio

18.12

Dividend/share

$6.25

EPS

$12.33

Enterprise value

$155.92B

Sector: Healthcare
Industry: Drug Manufacturers - General
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Highlights

Amgen's equity has increased by 12% from the previous quarter
The revenue has grown by 3.1% year-on-year
AMGN's quick ratio is up by 45% since the previous quarter but it is down by 34% year-on-year
The P/E is 25% below the 5-year quarterly average of 24.3 but 6% above the last 4 quarters average of 17.1
The debt rose by 12% year-on-year and by 7% since the previous quarter
The net income has contracted by 8% YoY and by 4.9% from the previous quarter

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
585.69M
Market cap
$130.84B
Enterprise value
$155.92B
Valuations
Price to earnings (P/E)
18.12
Price to book (P/B)
12.33
Price to sales (P/S)
5.41
EV/EBIT
16.3
EV/EBITDA
12.37
EV/Sales
6.42
Earnings
Revenue
$24.3B
EBIT
$9.57B
EBITDA
$12.6B
Free cash flow
$10.21B
Per share
EPS
$12.33
Free cash flow per share
$17.36
Book value per share
$18.12
Revenue per share
$41.33
TBVPS
$55.08
Balance sheet
Total assets
$65.01B
Total liabilities
$54.35B
Debt
$34.22B
Equity
$10.66B
Working capital
$12.37B
Liquidity
Debt to equity
3.21
Current ratio
2.18
Quick ratio
1.6
Net debt/EBITDA
1.99
Margins
EBITDA margin
51.9%
Gross margin
78.2%
Net margin
30%
Operating margin
37.9%
Efficiency
Return on assets
11.9%
Return on equity
71.7%
Return on invested capital
22.5%
Return on capital employed
17.6%
Return on sales
39.4%
Dividend
Dividend yield
2.8%
DPS
$6.25
Payout ratio
50.7%

AMGN stock price

How has the Amgen stock price performed over time

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$24.3B
Gross profit
$19.01B
Operating income
$9.2B
Net income
$7.3B
Gross margin
78.2%
Net margin
30%
The net margin has declined by 11% year-on-year and by 6% since the previous quarter
The company's operating margin fell by 9% YoY and by 5% QoQ
The net income has contracted by 8% YoY and by 4.9% from the previous quarter
AMGN's operating income is down by 7% year-on-year and by 3.7% since the previous quarter

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
18.12
P/B
12.33
P/S
5.41
EV/EBIT
16.3
EV/EBITDA
12.37
EV/Sales
6.42
The P/E is 25% below the 5-year quarterly average of 24.3 but 6% above the last 4 quarters average of 17.1
AMGN's EPS is down by 4% since the previous quarter and by 2.9% year-on-year
The stock's price to book (P/B) is 62% more than its 5-year quarterly average of 7.6 but 3.7% less than its last 4 quarters average of 12.8
Amgen's equity has increased by 12% from the previous quarter
The revenue has grown by 3.1% year-on-year
The P/S is 2.1% more than the 5-year quarterly average of 5.3

Efficiency

How efficient is Amgen business performance
The ROIC has grown by 18% YoY but it has contracted by 2.6% from the previous quarter
AMGN's return on sales is down by 12% year-on-year and by 7% since the previous quarter
The ROE has grown by 9% YoY but it has contracted by 4.5% from the previous quarter
AMGN's return on assets is down by 7% since the previous quarter and by 4% year-on-year

Dividends

What is AMGN's dividend history
DPS
$6.25
Dividend yield
2.8%
Payout ratio
50.7%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 20% more than its total liabilities
AMGN's quick ratio is up by 45% since the previous quarter but it is down by 34% year-on-year
Amgen's current ratio has increased by 37% from the previous quarter but it has decreased by 25% YoY
AMGN's debt to equity is up by 13% YoY but it is down by 4.5% QoQ
The debt rose by 12% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.